Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Cameron Santoro is an associate editor for The Center for Biosimilars

Articles

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.

Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Patent thickets hinder biosimilar access, driving up costs and delaying affordable treatments. Discover legislative solutions to enhance competition and patient care.

Clearing the Thicket: New Report Outlines Legislative Fixes to Boost Biosimilar Access

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions.

New Approvals Expand Access to Biosimilars for Ophthalmology, Bone, and Joint Conditions

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

The Center for Biosimilars - Biosimilars, Health Economics & Insights

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Understanding and Improving Access of Biosimilars in Oncology

Videos

Biosimilars in Oncology: Addressing Awareness

Current State of Biosimilars: Approval, Availability, and Efficacy

Biosimilars in Oncology: Equivalency and Cost

Are Biosimilar Costs a Factor for Patients?

Biosimilars: Addressing Roadblocks to Market Adoption

Switching to Available Biosimilars in Oncology

Determining Biosimilars' Role in the Formulary

Market-Access Considerations for Biosimilars in Oncology

Where Do Biosimilars Fit in to the Treatment Landscape?

Multiple Biosimilars for a Single-Reference Biologic  

Strategies for Incorporating Biosimilars Into Care Plans

Incorporating Biosimilars in Oncology: Working Collaboratively

Economic Impact of Biosimilars in Oncology

Biosimilars in Oncology: Long-Term Financial Benefit

Competition in the Biosimilar Marketplace

Biosimilars in Oncology: Future Directions